SUBSCRIBE
SUBSCRIBE
News   Policy

Dr. Reddy’s Laboratories Ltd.'s Announces Settlement Of Imitrex® Litigation With GlaxoSmithKline

October 10, 2006 | 
1 min read
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE:RDY) announced today that it has settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline’s Imitrex® tablets.
Legal Asia
GlaxoSmithKline
MORE ON THIS TOPIC
President Donald Trump calls out the first patient to access his TrumpRx drug platform during his State of the Union address at the U.S. Capitol on Tuesday, February 24, 2026.
Drug pricing
Trump Calls on Congress To Codify Most Favored Nation Drug Pricing in SOTU
February 25, 2026
 · 
2 min read
 · 
Annalee Armstrong
The white plane flies against the blue sky, leaving a white trail. Vector illustration
Vaccines
Postponed ACIP Meeting Rescheduled for Mid-March
February 25, 2026
 · 
3 min read
 · 
Tristan Manalac
Dollar boat swimming on paper waves
Startups
Harbour Cofunds Cancer Startup, Hands Off Clinical-Stage Antibody
February 25, 2026
 · 
2 min read
 · 
Tristan Manalac
Business people shaking hand in China.
GLP-1
Pfizer Builds Global GLP-1 Strategy With up to $495M Sciwind Deal
February 24, 2026
 · 
2 min read
 · 
Tristan Manalac